New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023

Allschwil, Switzerland – June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertensio...

Related Keywords

Perth ,Western Australia ,Australia ,Allschwil ,Switzerland General ,Switzerland ,Japan ,United States ,Dublin ,Ireland ,America ,American ,Swiss ,Andrewc Weiss ,Markus Schlaich ,Arthurc Corcoran ,Arterioscler Thromb Vasc ,J Physiol Pharmacol ,Clozelm Aprocitentan ,European Society Of Cardiology ,American Heart Association ,Idorsia Ltd ,Idorsia Pharmaceuticals Ltd ,Janssen Biotech Inc ,University Of Western Australia Royal Perth Hospital ,Janssen Pharmaceutical Companies Of Johnson ,Swiss Exchange ,Head Of Investor Relations Corporate Communications ,International Society Of Hypertension ,Hypertension Council ,European Society Of Hypertension ,European Society ,European Meeting ,Royal Perth Hospital ,Late Breaking Science ,Scientific Sessions ,African American ,North America ,International Society ,Executive Committee ,Management Board ,Measurement Month ,Hypertension Australia ,High Blood Pressure ,Folkow Award ,Editorial Board ,Janssen Biotech ,Janssen Pharmaceutical Companies ,Rev Pharmacol ,Factor Collaboration ,Thromb Vasc Biol ,Clin Hypertension ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,